ALTERNATING USE OF DIFFERENT JAK1/JAK2 INHIBITORS, A POSSIBLE THERAPEUTIC STRATEGY USEFUL IN PRIMARY MYELOFIBROSIS: A CASE REPORT

被引：0
|
作者：
Gutierrez, Lopez de Ocariz X. [1 ]
Vera, Guerrero E. [1 ]
Carreno, Gomez-Tarragona G. [1 ]
Buendia, Urena B. [1 ]
De Nicolas, Sol R. [1 ]
Hidalgo, Soto M. [1 ]
Lopez, Munoz N. [1 ]
Zamanillo, Herreros, I [1 ]
Iniguez, Garcia R. [1 ]
Poza, Santaella M. [1 ]
Ayala, Diaz R. [1 ]
Martinez, Lopez J. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-059
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [1] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [2] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [3] Prevention of Islet Inflammatory Stress with JAK1/JAK2 Inhibitors
    Watson, Eleanor
    Waibel, Michaela
    Trivedi, Prerak
    Pappas, Evan
    Fynch, Stacey
    Sutherland, Robyn
    Kay, Thomas
    Thomas, Helen
    TRANSPLANTATION, 2018, 102 : S370 - S370
  • [4] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    Pardanani, A.
    Laborde, R. R.
    Lasho, T. L.
    Finke, C.
    Begna, K.
    Al-Kali, A.
    Hogan, W. J.
    Litzow, M. R.
    Leontovich, A.
    Kowalski, M.
    Tefferi, A.
    LEUKEMIA, 2013, 27 (06) : 1322 - 1327
  • [5] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    R R Laborde
    T L Lasho
    C Finke
    K Begna
    A Al-Kali
    W J Hogan
    M R Litzow
    A Leontovich
    M Kowalski
    A Tefferi
    Leukemia, 2013, 27 : 1322 - 1327
  • [6] Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
    Raut, Lalit
    BLOOD RESEARCH, 2013, 48 (01) : 67 - 67
  • [7] MOMELOTINIB HYDROCHLORIDE JAK1/JAK2 inhibitor Treatment of myelofibrosis Treatment of pancreatic cancer
    Price, S.
    George, T.
    Pinilla-Ibarz, J.
    DRUGS OF THE FUTURE, 2015, 40 (09) : 561 - 568
  • [8] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
    Verstovsek, Srdan
    Kantarjian, Hagop
    Mesa, Ruben A.
    Pardanani, Animesh D.
    Cortes-Franco, Jorge
    Thomas, Deborah A.
    Estrov, Zeev
    Fridman, Jordan S.
    Bradley, Edward C.
    Erickson-Viitanen, Susan
    Vaddi, Kris
    Levy, Richard
    Tefferi, Ayalew
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1117 - 1127
  • [9] Preclinical characterization of JAK1/JAK2 inhibitors for treatment of type 1 diabetes
    Scott, N. A.
    Trivedi, P. M.
    Graham, K. L.
    Fynch, S.
    Jenkins, M. R.
    Kay, T. W.
    Thomas, H. E.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 361 - 361
  • [10] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    Jaekel, N.
    Behre, G.
    Behning, A.
    Wickenhauser, C.
    Lange, T.
    Niederwieser, D.
    Al-Ali, H. K.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 179 - 184
12345